BenchSci is a Toronto-based company with a focus on developing technology with artificial intelligence so that it can be used to expedite the research and discovery process for medicinal drugs. The technology is a platform that can be utilized for research purposes and can give researchers specific information on their intended experiment, thus reducing time spent on researching and planning materials.
The company has two platforms: the AI-Assisted Reagent Selection and the AI-Assisted Antibody Selection. The former platform has the capability of selecting the reagents for an experiment in as little as 30 seconds, when traditional research would take weeks. The latter platform aids researchers with finding appropriate products for the experiments using a database of more than 10 million scientific publications. The sources have been given independent validations from organizations such as The Human Protein Atlas and Encode. The academic versions of the platforms are free to appropriate institutions and the platforms can be accessed via payment for enterprise and commercial purposes.
David Qixiang Chen
Elvis Mboumien Wianda
The Entrepreneurship Hatchery (University of Toronto)
BenchSci raises $22 million for AI-powered drug discovery tools
February 4, 2020
We Are Trying To Build The Greatest Canadian Success Story In History: BenchSci CEO | Forbes India
November 28, 2019